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ABSTRACT

Scout Treadwell: The Effects of Alpha-Tocopherol and Ascorbic Acid on Metastatic
Breast Cancer Cells
Breast cancer is a multifaceted, complex disease that affects hundreds of
thousands of patients every year. Although there has a been a decline in the mortality rate
of this disease, it is still vital to investigate and discover new possible treatments. One
area of research involves the generation of reactive oxygen species (ROS) in cancer cells
and the possibility of ROS-induced apoptosis. Antioxidants such as Vitamin C and
Vitamin E have been shown to serve as pro-oxidants. Instead of detoxifying the cell from
damaging ROS, these compounds can stimulate ROS production, triggering an apoptotic
cascade in the cell. In this study, Vitamin C and Vitamin E at varying concentrations
were applied to four different cell lines, MCF-7, BOM-1883, MDA-MB-231, and MCF7-BOM. After the cells were treated, an SRB assay was performed in order to determine
the cell viability. The effects of hypoxia (low oxygen tension) on cancer cells was also
studied in this research. The results showed that MCF-7 cells were most susceptible to
Vitamin C treatment. Findings also showed that a hypoxic environment deceased cell
proliferation relative to normoxic control. The effects of Vitamin E were insignificant,
which is consistent with researched literature. However, the findings for Vitamin C were
of more interest because there have been several studies that have shown the positive
effects of Vitamin C as a pro-oxidant rather than an antioxidant in cancer cells.
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INTRODUCTION
CANCER
The human body is made of trillions of cells. Every day, these cells undergo
replication and division in order to support the ever-changing needs of the body.
Normally, there are checkpoints in the cell cycle to ensure controlled growth. However,
multiple factors such as inherited genes or even environmental factors like tobacco,
radiation, and ultraviolet (UV) rays break down this tightly regulated process because
deoxyribonucleic acid (DNA) has been altered in some way. Because cancer is related to
a change in DNA sequences, it can be considered a genetic disease. Once mutated, the
cells can ultimately resist responses that signal apoptosis or halt cell division. Cancer
cells are able to proliferate in response to their own signal, which causes rapid cell
growth, cell survival, and increased cell metabolism (Hanahan, 2011).
Drs. Hanahan and Weinberg have proposed eight hallmarks that constitute the
complexity of developed cancer. They include sustaining proliferative signaling, evading
growth suppressors, resisting cell death, enabling replicative immortality, inducing
angiogenesis, activating invasion and metastasis, dysregulating cellular energetics, and
avoiding immune destruction. They have also noted two enabling characteristics of
cancer. These characteristics include genome instability and mutation and tumorpromoting inflammation (Hanahan, 2011). Normally, proliferation is tightly controlled
by specific growth factors that are secreted by certain cells that instruct the entry and
progression through the cell growth-and-division cycle (Hanahan, 2011). This tightly
regulated process ensures growth homeostasis in cells. However, one of the fundamental
traits of cancer cells involves the ability to deregulate these growth signals and begin self-
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activated chronic proliferation. In the case of cancer, cells sustaining their own
proliferation begin to secrete their own growth factors and can increase the number of
growth factor receptors on the surface of the cell, which increases growth signal binding
and proliferation. While ensuring constant proliferation, cancer cells must also
circumvent signals that inhibit proliferation and growth. Tumor suppressor genes work to
limit cell growth and manages whether or not the cell proceeds through the growth and
division cycle. If deactivated, mutated tumor suppressor genes do not stop the
proliferation of cells and continual growth is possible. Apoptosis, often known as cell
death or cell suicide, serve as important regulator in cell balance. Apoptosis is a system
designed to kill cells when there is a disruption in the cell cycle, a mistake in the DNA or
if the cell has become old and damaged. Proteases, such as caspases 8 and 9, are activated
by certain signals. This activation leads to a cascade of events that ultimately disrupts the
integrity and disassembles the cells. Apoptosis remains a function of cells but there are
certain abnormalities that decrease cells’ susceptibility to apoptotic signals. Methods
cancer cells can use to limit apoptosis include the loss of tumor suppressor function and
downregulation of proapoptotic signals. Cancer cells must be able to replicate themselves
an infinite amount of times for tumor growth and metastasis. Replication immortality is
achieved through the alteration of telomeres. Telomeres protect the end of chromosomes
and can allow limited number of chromosomal replications. Telomeres shorten after each
replication. However, telomerase is a specialized DNA enzyme that adds telomere
repeats to the end of each chromosome. Through increased telomerase expression in
cancer cells, cells can ultimately divide at infinite levels because the telomere length is
never affected. In order for cancer cells to further survive, angiogenesis, the development
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of new blood vessels, is necessary for tumor progression (Hildreth, 2009). New blood
vessels can feed nutrients and oxygen into the growing tumors resulting in increased rates
of growth and proliferation (Hildreth, 2009). Angiogenesis is stimulated by the secretion
of Vascular Endothelial Growth Factor (VEGF). The secretion of VEGF is triggered by
either hypoxia (oxygen depleted scenarios) or by oncogene signaling (Hanahan, 2011).
The VEGF then binds to specific tyrosine kinase receptors known as Vascular
Endothelial Growth Factor Receptors (VEGFR). Angiogenesis contributes to the
microenvironment of cancer cells ensuring ample nutrition of growth, proliferation, and
metastasis. Once cells begin the road of rapid, unwanted growth, tumors can form. In
tumor cells, there is reprogramming of metabolism to support continuous cell growth
(Hanahan, 2011). These adjustments fuel further cell growth and division. In the
dysregulating of cellular energetics, there is a metabolic switch from aerobic to anaerobic
metabolism. This change calls for an up regulation in glucose transporters, like glucose
transporter 1 (GLUT1), that increases the glucose importation to the cytoplasm. The
increased glucose uptake can be visualized via positron emission tomography (PET) with
a radio-labeled analog of glucose, 18F-glurodeoxyglucose, (FDG) as a reporter for the
PET scan (Hanahan, 2011). Cancer cells are also able to avoid immune destruction.
Typically, the immune system is triggered by certain antigens. The system is then capable
of killing these irregular cellular formations. However, cancer cells resist the eradication
from immune cells therefore limiting the extent of immunological killing. The immune
system is typically suppressed in cancer cells resulting in deficiencies of cytotoxic T
lymphocytes (CTLs), helper T (HT) cells, and natural killer (NK) cells (Hanahan, 2011).
Because these components of the immune system are disabled, progressing tumor cells
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are able to evade immune attack. Cancer progression increases the rate of mutation. With
cancer cells, there is an increased sensitive to mutagenic agents. Typically, cells have
surveillance systems that monitor the genome integrity, but this has been found to be
compromised by cancer cells (Hanahan, 2011). Genes that detect DNA and genome
damage are suppressed by tumor progression, very similar to the suppression of tumor
suppressor genes. Tumor cells can also mirror inflammatory conditions. This
inflammation can supply bioactive molecules, like growth factors, to the tumor
microenvironment (TME) that sustain proliferation and signaling and also molecules that
lead to the of epithelial-mesenchymal transition EMT. It has also been shown that
inflammatory cells can release chemicals like ROS (Hanahan, 2011).

Sustaining Proliferative
Signaling
Evading Growth
Suppressors

•Secretion of Growth Factors

•Deactivating tumor suppressor genes

Resisting Cell Death

•Downregulation of Proapoptotic Signals

Enabling Replicative
Immortality

•Telomerase Expression

Inducing Angiogenesis

•Secretion of Vascular Endothelial Growth Factor (VEGF)

Activating Invasion and
Metastasis

•Epithelial-Mesenchymal Transition (EMT)

Dysregulation Cellular
Energetics

•Anerobic metabolism switch

Avoiding Immune
Destruction

•Immune System Suppression

Figure 1: Hallmarks of Cancer. Adapted from Hanahan and Weinberg 2011.
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Once a tumor develops, it can either be classified as benign or malignant. Benign
tumors are considered non-cancerous because they do not invade or spread into other
tissues in the body. Contrastingly, malignant tumors are capable of spreading throughout
the body. New tumors stemming from an original site is a result of this metastasis. Tumor
cells metastasize moving through the circulatory or lymphatic system from tissue to
tissue. Metastasis happens in a multistep process starting with local invasion and the
climax of metastasis resulting in the escape of cancer cells from the lymphatic or
circulatory system and the formation of small modules of cancer cells. Local invasion
occurs when the cancer cells undergo EMT, travel through the body, then and attach to
each other or healthy cells in the extracellular matrix (ECM) through a mesenchymalepithelial transition (MET) resulting in an increase in epithelial cadherin proteins and
local cell to cell adhesion. The EMT process allows cancer cells to travel through the
body and MET allows them to colonize again. Increasing growth in additional tissues is
officially considered cancer colonization (Hanahan, 2011). Once detected and biopsied, a
treatment plan can be created to ensure the best possible outcome for the patient.
Depending on the type of cancer and the stage, the survival rate and treatment plan can
look extremely different.
BREAST CANCER
Breast cancer is considered the second most common form of cancer in women
after skin cancer. In 2018, 252,710 women in the United States were diagnosed with
Breast Cancer and over 40,000 of those diagnoses ended in death (“Breast Cancer
Statistics and Resources”, 2019). While the mortality rate of cancer for breast cancer has
decreased over the years, diagnosis is still very prevalent among women. This decrease in
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mortality can be directly attributed to new treatments as well as early detection in women
through mammograms. However, despite advances in medicine, it is still said that one in
every eight women will be diagnosed with some form of breast cancer in their life
(“Breast Cancer Risk in American Women”, 2012). Further research and coming to
understanding the signs, symptoms, metabolism and metastasis of breast cancer is crucial
to further decrease the prevalence of breast cancer in the United States.
Similar to all types of cancer, breast cancer is a tumor formed by uncontrolled cell
growth and apoptosis. This specific malignancy begins in the breast tissue known as
lobules which are the glands responsible for breast milk production (“Breast Cancer
Statistics and Resources”, 2019). While the specific cause of breast cancer can be
difficult to determine, there are multiple factors which can contribute to development.
Inherited genes are considered to play an important role in determining a woman’s risk of
being diagnosed with breast cancer. Accumulation of altered genes can result in the
activation of a proto-oncogene to an oncogene or deactivation of tumor suppressor genes
(Luo, 2001). Normally, proto-oncogenes are vital to the healthy growth of cells. Once
mutated to oncogenes, cells begin to grow and divide at a dangerous rate (“Oncogenes
and Tumor Suppressor Genes”, 2015). Tumor suppressor genes assist in slowing down
the division of cells and in the control of apoptosis. If mutated, tumor suppressor genes
no longer function correctly and therefore cannot continue to regulate cell division
resulting in rapid cell growth and inability to commit cell suicide. It is estimated that
around 10% of breast cancers are due to hereditary predisposition (Luo, 2001). Breast
cancer has been linked to the inheritance of two tumor suppressor genes, BRCA 1 located
on chromosome 17 and BRCA 2 located on chromosome 13 (Luo, 2001). Although not
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specifically inherited, a woman’s chance of developing breast cancer increases if there is
a family history of the disease in close relatives such as the mother, grandmother or sister
(“Breast Cancer Risk in American Women”, 2012). Also, having a male relative with a
history of breast cancer can increase one’s chances of development (“Breast Cancer Risk
in American Women”, 2012). Other risk factors include heavy alcohol consumption,
obesity and being physically inactive. Out of all ethnic groups, breast cancer is diagnosed
more often in white women compared to African Americans, Hispanics, or Native
Americans.
BREAST CANCER STAGING
When caught early, most forms of breast cancer are considered potentially
curable. Because of this, regularly scheduled mammograms have become increasingly
important for women. Mammography has been shown to increase the survival rate of
breast cancer patients. However, not all women receive adequate screening. In a 1992
study of 8,805 women aged 50 to 74 years old only 47% of the women received a
mammogram. Of this 47% there were increased mammography rates of between 3%-5%
were observed for white, married, women in the higher estimated household income
group (McCarthy, 2018). Education and stressing the importance of regularly scheduled
mammograms is crucial to decrease the mortality rate of breast cancer. Through
mammograms, breast cancer lumps can be detected before symptoms have developed
(“Breast cancer Statistics and Resources”, 2019) Through the screening, if a mass is
discovered it will either be categorized as benign or malignant. If the mass is benign,
simple procedures can be conducted in order to remove the mass, if the patient so desires.
On the other hand, if the mass is predicted to be cancerous, a biopsy is necessary to
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determine the exact stage of cancer the mass is which is vital to an effective treatment
plan. Breast biopsies are procedures which involve removing a small part of the breast
lump in order for further testing (“Breast Biopsy”, 2019). While the specific procedure
can vary depending on the size of the lump or its position, usually a small needle is
placed in the lump and cells and fluid are extracted. In some cases, a surgical biopsy may
be necessary in order to remove the entire mass for a more in-depth tissue analysis. To
determine if breast cancer has become invasive, often doctors will biopsy the underarm
lymph nodes, as this is the first-place breast cancer tends to spread (“Breast Cancer
Stages: 0 Through IV”, 2019). Test results can reveal if the mass is cancerous or not as
well as the stage of the cancer (“Breast Biopsy”, 2019). There are several hormonal
markers that are used for breast tumor subtyping. These include the status of estrogen
receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2)
(Dai, 2016). Testing of these markers are routine in breast cancer pathology. These
hormonal and growth receptors are important in cell growth mediation. If a tumor is ER
or PR positive, the cancer cells may receive signals from estrogen or progesterone that
promote growth (Dai, 2016). The proto-oncogene protein, HER2, promotes the growth of
cancer cells. Protein expression is commonly amplified in cancer cells. Protein
expression can be assayed by immunohistochemistry technique (IHC). Treatments that
can target HER2 proteins are typically very successful if the tumor is HER2 positive.
Through detection and biopsy, the stage and type of cancer can be determined.
There are two very different types of breast cancer. In situ cancer is used to describe
cancer that is noninvasive and stays within the milk ducts or lobules in the breast. On the
other hand, more than 80% of breast cancers are invasive and infiltrate surrounding or
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distant tissues through breaking through breast glands and ducts (“Breast Cancer
Statistics and Resources”, 2019).

Figure 2: In Situ Non-Invasive Cells vs. Invasive Cells. This image compares the cells in
a tumor. With noninvasive cells, the tumor is compact. With the invasive tumor, cells
have begun to leave the cellular environment and at this point can spread to other parts of
the body. Figure constructed by author.
The stage of cancer shows how much the tumor has progressed or if it has spread
to neighboring tissues. Breast cancer is staged on a number scale from 0 to IV with 0
being noninvasive cancer and IV being metastatic cancer (“Breast Cancer Stages: 0
Through IV”, 2019). The Tumor, Node, Metastasis (TNM) system is a specific staging
system defined by the American Joint Committee on Cancer that classifies stages so there
can be a uniform discussion of the disease for all physicians (“Breast Cancer Stages: 0
Through IV”, 2019). The system is as follows, T: the size of the cancer tumor and
whether or not it has grown into nearby tissues, N: whether the cancer is in the lymph
nodes, and M: whether the cancer has spread to other parts of the body beyond the breast
(“Breast Cancer Stages: 0 Through IV”, 2019). There are further staging guidelines to
determine the extent of breast cancer. Stage 0 describes noninvasive breast cancers where
the abnormal cells have not broken out of the breast. Stage I is used to describe breast

9

cancer that has spread into neighboring tissues. This stage is broken into two
subcategories IA and IB. Stage IA is the case where the breast cancer is only two
centimeters and the lymph nodes have not been invaded. IB is the diagnosis when there
are no cancer cells in the actual breast but rather small groups of cancer cells no larger
than two millimeters are found in the lymph nodes or maximum two-centimeter mass
along with small groups of cancer cells in the lymph nodes. Stage II breast cancer also
has two subcategories. Stage IIA is used to describe breast cancer in which the cancer in
the lymph nodes is larger than two millimeters or the tumor is larger than two centimeters
but smaller than five centimeters. Stage IIB is the situation in which the tumor is between
two and five centimeters and there are small groups of cells in the lymph nodes or if the
tumor is larger than five centimeters, but the cells have not spread to axillary lymph
nodes. Stage III has three subcategories; IIIA, IIIB, and IIIC. Stage IIIA is when the
tumor is larger than five centimeters and small groups of cells are found in the lymph
nodes. Stage IIIB describes a situation in which the tumor may be any size, but it has
spread to the chest wall and or skin of the breast. Stage IIIC describes breast cancer that
has either invaded to ten or more axillary lymph nodes or has spread above the axillary
lymph nodes and moved into the collarbone. Stage IV is used to describe breast cancer
that has spread beyond the breast or axillary lymph nodes and has invaded tissues such as
lung, bone, skin, liver or brain (“Breast Cancer Stages: 0 Through IV”, 2019). The actual
process of metastasis is still considered to be somewhat enigmatic; however, studies have
shown that there are preferential organs and tissues that breast cancer may spread to
(Chen, 2018). This non-random preferential metastasis is known as organotrophic
metastasis. Tumor cells have the ability to interact with the extra cellular matrix to
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facilitate metastasis and initiate growth. Invasive breast cancers can be categorized into to
subcategories; invasive ductal carcinomas (IDC) or invasive lobular carcinomas (ILC)
(Chen, 2018). The IDC preferentially metastasize to lungs, distant lymph nodes, and the
central nervous system. Meanwhile, ILC has three times the frequency of metastasis into
the peritoneum, gastrointestinal tract, and ovaries (Chen, 2018). By identifying the
particular stage the breast cancer is in, an accurate treatment plan can be established for
the patient.
Depending on the Stage and type of breast cancer, the treatment plan can differ.
There are several types of cancer treatments including chemotherapy, surgery, radiation,
and hormone therapy. In some cases, oncologists will opt to use a combination of these
treatments in order to best fight the cancer. If possible, surgery will be performed initially
to remove tumor masses. Mastectomies are commonly performed to remove breast
cancer. There are varying mastectomy surgeries that vary in levels of invasiveness. Total
mastectomies (TM) are the removal of the total breast, overlying skin and nipple (Shah,
2014). Skin-sparing mastectomies (SSM) which conserve as much skin as possible.
Modified radical mastectomies (MRM) involve complete removal of the breast as well as
a large portion of the pectoral muscles and axillary lymph node dissection. There are also
prophylactic mastectomies (PM) in which a patient may opt for to lower their chances of
a breast cancer diagnosis if they are positive for the breast cancer genes BRCA1 and
BRCA2. Postsurgical treatments may be used if the entire tumor is not removed. While
chemotherapy treatments may differ, they all attack quickly dividing cells in the human
body. Chemotherapy is often used as a neoadjuvant therapy before surgical removal to
decrease the size of the tumor. Chemotherapy treatment can cause many deleterious side
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effects for patients due to the cytotoxicity of the chemicals used. Radiation, at a high
energy levels, aims to destroy cells’ DNA resulting in cell cycle arrest for cancer cells. If
the cancer is hormone-receptor-positive, hormonal therapies can be used to block or
lower the levels of hormones in the body that will ultimately halt cancer progression. If
the cancer is hormone-receptor-negative, it will be unreceptive to hormonal therapy. All
of these treatment options can increase the overall survival for patients, but it is important
to continue to research new methods that may be more beneficial and less toxic to the
patients.
IMPORTANCE OF RESEARCH
Researching and finding a cure for cancer brings hope to those struggling with the
disease or those who are survivors and already fought the battle. Advances in medicine
have provided new options for treating breast cancer, decreased the mortality rate, and
increased the survival rate. Through additional research, both the quality of life and
quantity of life saved can be improved for patients. However, the fear of cancer does not
end once a patient is declared in remission. There are future concerns of recurrence,
fertility issues, or the genetic effect on future offspring (Leigh, 2000). Survivors yearning
to feel empowered by their battle have politically pushed for an increase in government
funded cancer research hoping to eventually decrease the cost of treatment (Leigh, 2000).
Financial burden should not be a patient’s major concern while they are fighting for their
lives. Continued research of the most effective treatment plans can have positive effects
on the price tag behind being diagnosed with cancer. Increasing patient access to clinical
trials and education regarding early detection can further improve cancer prevention
methods and quality of care if diagnosed.
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NATURAL PRODUCTS
There are several products in nature that can be researched in order to determine
their potential for treating cancer. In particular, ascorbic acid (Vitamin C) and alpha
tocopherol (Vitamin E) have been studied to understand their antioxidant effects on
cancer. Vitamin C and Vitamin E can both be found in a variety of natural food sources.
Vitamin C is found in many leafy greens like broccoli and kale as well as citrus fruits like
kiwi and oranges. Vitamin E is most commonly found in vegetable oils such as sunflower
seed oils or nuts, like peanuts and almonds.
Vitamin C is an essential cofactor for α-ketoglutarate-dependent dioxygenases.
Examples are prolyl hydroxylases, which play a role in the biosynthesis of collagen and
in the down-regulation of hypoxia-inducible factor (HIF)-1, a transcription factor that
regulates many genes responsible for tumor growth, energy metabolism, and neutrophil
function and apoptosis (Traber, 2011). Vitamin C-dependent inhibition of the HIF
pathway may provide alternative or additional approaches for controlling tumor
progression, infections and inflammation. Vitamin E functions as an essential lipid
soluble antioxidant, scavenging hydroperoxyl radicals in lipid milieu (Traber, 2011).
Human symptoms of vitamin E deficiency suggest that its antioxidant properties play a
major role in protecting erythrocyte membranes and nervous tissues. As an antioxidant,
vitamin C provides protection against oxidative stress-induced cellular damage by
scavenging reactive oxygen species, vitamin E-dependent neutralization of lipid
hydroperoxyl radicals, and by protecting proteins from alkylation by electrophilic lipid
peroxidation products (Traber, 2011).
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Figure 3: Vitamin E Molecular Structure.

Figure 4: Vitamin C Molecular Structure.

CANCER AND MITOCHONDAL RESPIRATION
All cells undergo oxidative phosphorylation in the mitochondrial matrix if there is
oxygen present. Respiration is a series of reactions in which electrons are passed on
through the mitochondrial electron transport chain with oxygen serving as the final
electron acceptor. Once oxygen is reduced to water, the process can begin again.
Respiration and the reduction and oxidation of electron carriers allows for adenosine
triphosphate (ATP) production which is our source of energy in the body. Mitochondrial
metabolism is a tightly regulated process.
This tightly regulated system can become leaky and oxygen can be partially
reduced to a superoxide anion (O2-) (Hoeks, 1970). The mitochondrial leak typically
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occurs in complexes I and III of the electron transport chain (Nita, 2016). However, there
are multiple pathways in which ROS production can be stimulated. Antioxidants, found
in many foods and other natural products, are used in order to avoid the formation of
oxide radicals because these radicals can harm and age cells via oxidative damage.
Reactive oxygen species (ROS) are used to describe a variety of molecules and free
radicals (Hoeks, 1970). Oxygen, the eighth element of the periodic table, is a colorless
gas at room temperature with two unpaired electrons in its outer shell. Because both of
these electrons have the same spin in the ground state, oxygen is not typically a reactive
species (Hoeks, 1970). However, when partially reduced by one electron at a time, the
superoxide radical becomes the precursor for many ROS (Hoeks, 1970). This precursor
can be converted to hydrogen peroxide (H2O2) and then further broken down to water
(H2O). Low levels of ROS production are required for physiological functions such as
normal cell proliferation, signal transduction, and gene expression (Nita, 2016).
Hydrogen peroxide (H2O2) is an important secondary chemical messenger in cellular
signaling (Liou, 2010). At lower levels, hydrogen peroxide can stimulate cell
proliferation in cancer cells and also upregulates messenger ribonucleic acid (mRNA)
levels of cyclins that participate in the cell cycle (Liou, 2010). Oxidative stress is any
state where there is an excessive level of ROS and an imbalance of antioxidants. High
ROS levels can damage cellular proteins, lipids and DNA leading to disruptions in cells
that can contribute to carcinogenesis (Liou, 2010).
Under normal conditions, there are several pathways in the body that are designed
to detoxify cells from high levels of ROS to avoid oxidative damage. Glutathione (GSH)
is an antioxidant that protects cells from oxidative stress. In this system, disulfide bonds
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(S-S) are reduced to thiol group (SH). Glutathione is oxidized to glutathione disulfide
(GSSG) which allows for the breakdown of hydrogen peroxide (H2O2) to water (H2O)
and GSSG is reduced to refill the GSH pool to combine with another cysteine when
another reaction needs to take place (Liou, 2010). This system can control the oxidative
equilibrium in cells. Elevated rates of reactive oxygen species (ROS) have been detected
in almost all cancers, where they promote many aspects of tumor development and
progression. However, tumor cells also express increased levels of antioxidant proteins to
detoxify from ROS, suggesting that there is a delicate balance of intracellular ROS levels
that is required for cancer cell function (Liou, 2010). If ROS levels remain at high levels,
DNA will be further damaged, and cells will go into a series of apoptosis cascades. If
antioxidant levels are too high, ROS levels will decrease, and the tumor will progress and
grow even more. This conundrum shows the balance of ROS and antioxidants in cancer
cells. Treatments can focus on tipping the balance to ROS-induced apoptosis signaling in
cancer cells which will decrease tumor progression.
Apoptosis is a vital process that maintains the integrity of cells. It is a tightly
regulated process but with an increase in intracellular ROS, cell cycle arrest and
apoptosis may be induced (Liou, 2010). ROS, such as H2O2 and superoxide radical (O2-)
can trigger the release of cytochrome c from the mitochondria which begins an apoptosis
cascade (Redza-Dutordoir, 2016). Mitochondrial release of H2O2 can lead to the
activation of c-Jun N-terminal kinases (JNKs) (Liou, 2010). In the presence of increased
mitochondrial ROS levels, JNKs catalyze the phosphorylation and downregulation of
anti-apoptotic proteins such as B-cell lymphoma 2 (BCL-2) (Liou, 2010). BCL-2 has
been seen to inhibit apoptosis by blocking the oligomerization of BAX/BAK. This
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oligomerization leads to the release of apoptotic signals from the mitochondria. If BCL-2
is downregulated, BAX/BAK can bind stimulating apoptotic cascades (Tzifi, 2011).
Progression through this pathway releases cytochrome c that triggers a further apoptosis
cascade. High levels of ROS can induce the expression of the p53 gene. This gene plays a
crucial role in regulating apoptotic signals, such as targeting the upregulation of BAX and
BAK, that will lead the cell into the intrinsic pathway and ultimately cell death (RedzaDutordoir, 2016). Members of the mitogen activated pathway kinase (MAPK) have also
been implicated in apoptotic signaling in response to increased ROS generation. The
MAPK pathway is composed of a series of serine/threonine specific protein kinases that
controls genes transcription, cell growth, and apoptosis. This pathway is activated via a
phosphorylation change between specific serine and threonine residues on target proteins
(Hellmich, 2007).
Antioxidants, like Vitamin E and Vitamin C, have been shown to inhibit tumor
cell proliferation (Liou, 2010). Important in the relation of anticarcinogen and prooxidative action is that high concentrations of Vitamin C has been shown to induce cell
death and apoptosis in various tumor cell lines (Rietjens,2002). At higher concentrations,
it acts as a pro-oxidant by inducing ROS (Chakraborthy, 2014). Whether Vitamin C has a
net pro-oxidant or antioxidant effect depends on the concentration gradient and redox
state of a cell (Chakraborthy, 2014). Vitamin E is less consistent with its pro-oxidant
activities. Several other studies have reported Vitamin E to be a tumor initiating and
tumor promoting carcinogen and does not demonstrate cancer preventative effects (Yang,
2013). High levels of antioxidants can begin to detoxify the ROS in cells leading to
further proliferation of the tumor. At these higher levels, tumors may become well-
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adapted to the oxidative stress and develop enhanced, endogenous antioxidant capacity
(Liu, 2018). At certain levels, particularly low doses, ROS can actually stimulate cell
proliferation in cancer cells (Liou, 2010). Angiogenesis, EMT, and cell cycle progression
can all be induced by low ROS levels. Because of this activation, it is important to
carefully manage the ROS levels in cells.
Hypoxia and oxygen levels have also been studied to show the importance in
cancer cells. Limitations in oxygen for a prolonged period can lead to tumor cell death
(Liou, 2010). However, tumor cells are capable of switching metabolic states to adapt to
low oxygen levels. This is known as the Warburg effect. This is a shift from aerobic
metabolism to anaerobic glycolysis. In poor oxygenated states, there is an increase in
HIF-1 expression which can contribute to cancer cell invasiveness. Elevated expression
and activation of HIF-1 protein can stimulate the production of the angiogenic growth
factor, VEGF, that recruits new blood vessels which provide further nutrients for the
tumor.
MATERIALS AND METHODS
Cell Culture/ Compound Treatment
Human breast tumor MCF-7 and MDA-MB-231 cells were obtained from the
American Type Culture Collection. The bone metastatic MDA-MB- 231 derived BOM1883 and MCF-7-derived MCF-7 BOM subclones were originally isolated by Dr. J.
Massagué’s group at Memorial Sloan Kettering Cancer Center, New York City, New
York and obtained from Dr. Kounosuke Watabe at Wake Forest University Baptist
Medical Center, Winston-Salem, North Carolina.
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The MCF-7 is a cell lined was established by Dr. Soule in 1973 at Michigan
Cancer Foundation. These cells are derived from a 69-year old woman with metastatic
breast cancer (Comşa, 2015). Breast MCF-7 cells are estrogen receptor (ER)-positive and
progesterone receptor (PR)-positive (Comşa, 2015). The MDA-MB-231 cell line is
derived from a patient with invasive ductal carcinoma. The cell line is ER, PR, and
epithelial-cadherin negative (Welsh, 2013). The MDA-MB-231 cells also do not
overexpress the HER2 growth factor receptor, so they serve as an excellent model for
triple-negative breast cancer (Welsh, 2013). The BOM-1883 line was derived from
MDA-MB-231 parental cell line and is a bone metastasis–prone subline (Y. Kang, K.
Pantel, Cancer Cell 23, 573-581 (2013)). The MCF-7 BOM line is also a bone
metastasis–prone subclone, derived from the MCF-7 parental cell line (Cancer Research,
2013, DOI: 10.1158/0008-5472.CAN-12-2037). All cell lines were maintained in RPMI1640 Medium with L-glutamine 2 mM (HyClone, SH30027.02) supplemented with fetal
bovine serum [FBS, 10% (v/v)] (Hyclone, 30910.03), penicillin (100 units/mL) and
streptomycin (100 μg/mL) (ThermoFisher Scientific, 15140163).
Sulforhodamine B (SRB) Viability Assay
The SRB viability assay was performed to determine cell viability in 96-well
plate-based format. SRB assays are used to investigate cytotoxicity in cell-based studies
(Orellana, 2016). Exponentially grown cells maintained in 10 cm plates (Nunc) were
trypsinized with 1 mL 0.25% Trypsin (Gibco, 2520056). They were then collected with
10 mL of 10% fetal bovine serum (FBS) RPMI1640 media. The cells were then further
diluted with 10% FBS. A hemocytometer was used to count and determine cell density.
For the cell seeding procedure, cells were added in a volume of 100 μL per well into 96-
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well plates (Thermo Scientific-167542) at the specified densities of MCF 7: 30000
cells/well, MDA-MB-231: 20000 cell/well, BOM-1883: 15000 cells/well, and MCF-7
BOM: 15000 cells/well. For compound treatments of alpha-tocopherol (Vitamin E)
(Sigma-Aldrich T3251) and ascorbic acid (Vitamin C) (ACRO-40147100), working
dilutions prepared at 2x final concentrations in serum-free RPMI1640 media with
penicillin and streptomycin were added to the 96-well plates in a volume of 100 μL per
well. Vitamin E was dissolved in dimethyl sulfoxide (DMSO) (Sigma Aldrich-D2438)
and Vitamin C was dissolved in deionized distilled water. Two 96-well plates were
seeded for each experimental treatment to observe the effects a hypoxic environment has
on cell viability. For the normoxic environment, plates were placed in a humidified
atmosphere (5% CO2 and 95% air) at 37 °C. Cells exposed to the hypoxic environment
were placed in a chamber with a humidified environment of 1% O2/5% CO2/94% N2. The
four total plates incubated for 48 hours in their respective environments. Once the
incubation was complete, 100 μL of media was removed from each well. The fixation
process of the cells consisted of the addition of 100 μL of 20% trichloroacetic acid (TCA)
(Sigma-T9-159-250G) in 1x Phosphate Buffered Saline (PBS) (Fisher, BP399-1),
followed by incubation at 4°C for one hour. The plates were washed with tap water four
times before being placed in the hood to dry. The next day, 70 μL/well of 0.4%
Sulforhodamine B (SRB) (MP, 194599) in 1% acetic acid (Fisher Scientific-A38S-500)
was added to the 96 well plates in order to stain the fixed cells. After 10 minutes, the
plates were washed with 1% acetic acid (Fisher Scientific-A38S-500) three times. The
plates were then inverted and laid in the hood to dry. The following day, 100 μL of 10
mM Tris base (Fisher Scientific, BP152-1) was added to each well and every plate was
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shaken for three minutes. The plates were then analyzed using the SpectaFluor plate and
Magellan software at an absorbance range of 492-620 nm. The difference in absorbance
between 492 and 620 nm is used to calculate cell viability. The extent of OD values
correlate with the number of viable cells. From the data collected, results were interpreted
via Prism 8 software. Cell viability data are presented as ‘% Inhibition’ or ‘% Control’ as
specified, calculated using the formula:
% Inhibition = [1 – (ODcompound/ODcontrol)] × 100
% Control = ODcompound/ODnormoxic control × 100
The dilutions for the both compounds can be found below. The concentrations applied to
each well in the 96-well plates can be found below as well.

Table 1: Vitamin C Dilutions
Vitamin C Dilutions
(Final
concentrations)

Stock Dilution

Media Volume

300 μM

50.4 μL of 50 mM

4.15 mL

100 μM

1.1 mL of 300 μM

2.2 mL

30 μM

330 μL of 300 μM

2.970 mL

10 μM

330 μL of 100 μM

2.970 mL

1 μM

300 μL of 10 μM

2700 mL
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Table 2: Vitamin E Dilutions
Vitamin E Dilutions

Stock Dilution

Media Volume

300 μM

50.4 μL of 50 mM

4.15 mL

100 μM

1.1 mL of 300 μM

2.2 mL

30 μM

330 μL of 300 μM

2.970 mL

10 μM

330 μL of 100 μM

2970 μL

1 μM

300 μL of 10 μM

2700 μL

Table 3: Vitamin C Concentrations in a 96-Well Plate
MCF 7
1
A
B
C
D
E

2

BOM-1883
3

4

5

6

MD-MBA-231

MCF-7-BOM

7

10

9

Media Control 100 μL (negative control)
Media Control 100 μL (negative control)
1 μM Vitamin C
10 μM Vitamin C
30 μM Vitamin C

F

100 μM Vitamin C

G

300 μM Vitamin C

H

8

10 μM Cycloheximide (positive control)
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Table 4: Vitamin E Concentrations in a 96-Well Plate
MCF 7
1

2

BOM-1883
3

A

4

5

6

MD-MBA-231

MCF-7-BOM

7

10

8

9

11

12

Media Control 100 μL (negative control)

B

Media Control 100 μL (negative control)

C

1 μM Vitamin E

D

10 μM Vitamin E

E

30 μM Vitamin E

F

100 μM Vitamin E

G

300 μM Vitamin E

H

10 μM Cycloheximide (positive control)

RESULTS
The results below show the percent inhibition curves for the different cell lines
under normoxic and hypoxic conditions. The IC50 values can be found in the graphs
below. IC50 values represent the concentration of the test compound that results in 50%
inhibition. This is a measure of the effectiveness of a chemical suppressing a specific
biological function, in this case the proliferation/viability of tumor cells. This
measurement shows how much of a compound is needed to inhibit a process by half.
From these graphs, the IC50 value can be obtained from the linear regression graph
analysis. The IC50 values for the two different compounds can be found in Table 5.
Figure 5 and Figure 6.
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Figure 5A-H: Inhibition Tumor Cell Proliferation by Vitamin C after 48 hours at
various Concentrations
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Figure 6A-H: Inhibition of Tumor Cell Proliferation by Vitamin E after 48 hours
at Various Concentrations
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Figure 7A-D: Cell Proliferation/Viability after 48 hours under normoxic and hypoxic
conditions in the presence and absence of cycloheximide.
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Table 5: Vitamin C IC50 Values

Cell line

IC50 Value (M)

MCF-7 Normoxia

216

MCF-7 Hypoxia

15.7

BOM-1883 Normoxia

319

BOM-1883 Hypoxia

256

MDA-MB-231 Normoxia

869

MDA-MB-231 Hypoxia

6.008e+024

MCF-7-BOM Normoxia

608520

MCF-7-BOM Hypoxia

226

Table 6: Vitamin E Tumor Cell Growth IC50 Values
Cell line

IC50 Value (M)

MCF-7 Normoxia

12460

MCF-7 Hypoxia

6.577e-033

BOM-1883 Normoxia

27255

BOM-1883 Hypoxia

105192

MDA-MB-231 Normoxia

52960

MDA-MB-231 Hypoxia

1.819e+095

MCF-7-BOM Normoxia

4523

MCF-7-BOM Hypoxia

2.873e-011
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DISCUSSION
It was expected that as the concentration of vitamin C and vitamin E increased in
the cells, more ROS would be generated and there would be a decrease in cell viability
due to ROS induced apoptosis. The MCF-7 cell line under both the normoxic and
hypoxic environment showed the greatest response to vitamin C. At a vitamin C
concentration of 300 μM, there was an average of 68% inhibition for the MCF-7
Normoxic condition with an IC50 value of 216 M. With a small IC50 value, the drug is
considered to be more effective because it takes less of the compound to reach 50%
inhibition. The MCF-7 cells in a hypoxic environment showed similar results with a
particularly low IC50 value of 15.7 M. These results can be viewed in Figures 4A and
4B. The remaining cell lines did not show profound results with varying concentrations
of vitamin C. This could be attributed to the fact that because MCF-7 is ER and PR
positive, the cell line can interact differently with the vitamins. When comparing to the
effects of vitamin C, vitamin E was less effective, as the vitamin E treatment did not
significantly affect the cell lines. This result can be visualized in Figure 5. There is little
research to show the effectiveness of Vitamin E as a pro-oxidant. However, there is
substantial evidence that vitamin E can promote tumor proliferation, instead of promoting
apoptosis. At certain concentrations of Vitamin E, you can see enhanced tumor activity.
There are studies that show that vitamin E has a biphasic effect which is stimulatory at 1
and 10 μM and inhibitory at 100 μM (ElAttar, 1992). This is an interesting finding and
can be used to explain why Vitamin E has varying capabilities at different concentrations.
The error in these results can be attributed to human error in improper cell seeding
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procedure. To improve the results, this experiment could be carried out multiple times
with more careful attention to the seeding of cells into the 96-well plates. Because
Vitamin E is not soluble, there could also be error in dilutions of this compound.
To further determine the effects of vitamin C and vitamin E, additional research
should be continued in order to measure the production of ROS by both of these
compounds. If it is found that there is negligible ROS production from vitamin C and
vitamin E, the experiment could be repeated with other pro-oxidants. Levels of ROS
production can be measured for fluorescent assays that measure DNA and RNA damage
as well as lipid peroxidation.
Figures 6 shows the results of tumor cell proliferation/viability under a hypoxic or
normoxic environment. The protein synthesis inhibitor cycloheximide was used as
positive control in this part of the experiment to suppress all cancer cells. Relative to
normoxia, the hypoxic environment decreased cell proliferation and viability. This is an
intriguing result, because there are situations in which a hypoxic environment can
upregulate the transcription of VEGF, resulting in the recruitment of new blood vessels to
the tumor for sustained proliferation. It is possible that in the absence of endothelial cells
to form new blood vessels, the increase in secreted VEGF protein levels does not
contribute to improved cell proliferation/survival.
To better understand the effects of ROS-induced apoptosis in cancer cells, there
could be a more in depth look into the depletion of the glutathione redox system. As
previously stated, glutathione is an important regulator in controlling the redox
environment of a cell. This system is responsible for ridding the cell of harmful ROS. If
the glutathione redox system was blocked or inhibited, ROS levels could possibility
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increase. The effect of this ROS increase has on cell viability could prove beneficial for
future therapeutic treatments.

CONCLUSION
In reflection, there are multiple pathways that can be targeted to reduce tumor
proliferation and promote apoptosis. Our hypothesis was that antioxidants, vitamin C and
vitamin E, have pro-oxidant capabilities. These compounds would be able to stimulate
ROS production which can lead to an oxidative stress environment in the cancer cell.
There have been several studies that have shown that at higher levels of ROS, apoptosis
can be induced through a variety of signaling cascades. The results from these
experiments is the deduction that vitamin C does have pro-oxidant activity in tumor cells.
This compound proved more effective on inhibiting tumor cells. The results were most
visible in the MCF-7 cell line. The results from vitamin E were inconclusive compared to
the results for vitamin C. Furthermore, the effect of a hypoxic environment decreased cell
proliferation in the experiments. Although the two compounds did not produce a
significant antitumor effect, these two ideas shed light into new ways that cancer can be
targeted. Further investigation of oxidative stress and the production of ROS in cancer
cells may produce more definitive results.
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